{
    "info": {
        "nct_id": "NCT03341806",
        "official_title": "Phase I Study of PD-L1 Inhibition With Avelumab and Laser Interstitial Thermal Therapy in Patients With Recurrent Glioblastoma",
        "inclusion_criteria": "* Patients must have histologically proven GBM from the initial resection.\n* Patients must have a life expectancy > 16 weeks. Patients must have a Karnofsky performance status of ≥ 60 or ECOG 0 - 2\n* Patient's requirement for dexamethasone should be ≤ 4mg daily or a stable dose at enrollment.\n* Patients must have adequate bone marrow, hepatic and renal function and hemoglobin and the test musts be performed within 14 days prior to study Day 1.\n* Highly effective contraception for both male and female subjects if the risk of conception exists.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known history of autoimmune disorder except diabetes mellitus type 1, vitiligo or hypothyroidism only requiring hormone replacement\n* Patients who have received any other therapeutic investigational agent within 30 days of enrollment with the exception of the personalized MTA vaccine (NCT03223103) that can be continued throughout the study.\n* Patients who have received any other therapeutic investigational agent within 30 days of enrollment or prior\n* Prior placement of intracavitary BCNU-impregnated wafers (Gliadel).\n* Prior treatment with checkpoint inhibitors, CTL-4 antibody or other immunotherapy agents\n* Presence of any other active malignancy or prior history of malignancy, except for: basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate carcinoma not requiring active treatment.\n* Prior organ transplantation, including allogeneic stem cell transplantation\n* Significant acute or chronic infections including, among others: HIV, AIDS, HBV\n* Pregnancy or lactation\n\nContact site for full inclusion/exclusion list.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a life expectancy > 16 weeks. Patients must have a Karnofsky performance status of ≥ 60 or ECOG 0 - 2",
            "criterions": [
                {
                    "exact_snippets": "life expectancy > 16 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 16,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Karnofsky performance status of ≥ 60",
                    "criterion": "Karnofsky performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ECOG 0 - 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient's requirement for dexamethasone should be ≤ 4mg daily or a stable dose at enrollment.",
            "criterions": [
                {
                    "exact_snippets": "requirement for dexamethasone should be ≤ 4mg daily",
                    "criterion": "dexamethasone dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "mg daily"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "requirement for dexamethasone ... or a stable dose at enrollment",
                    "criterion": "dexamethasone dose",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable at enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Highly effective contraception for both male and female subjects if the risk of conception exists.",
            "criterions": [
                {
                    "exact_snippets": "Highly effective contraception for both male and female subjects if the risk of conception exists.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": [
                                "male subjects",
                                "female subjects"
                            ]
                        },
                        {
                            "requirement_type": "risk of conception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have histologically proven GBM from the initial resection.",
            "criterions": [
                {
                    "exact_snippets": "histologically proven GBM",
                    "criterion": "glioblastoma multiforme (GBM) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation method",
                            "expected_value": "histologically proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "from the initial resection",
                    "criterion": "tumor sample source",
                    "requirements": [
                        {
                            "requirement_type": "source",
                            "expected_value": "initial resection"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Presence of any other active malignancy or prior history of malignancy, except for: basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate carcinoma not requiring active treatment.",
            "criterions": [
                {
                    "exact_snippets": "Presence of any other active malignancy",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of malignancy, except for: basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate carcinoma not requiring active treatment",
                    "criterion": "prior history of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "basal cell carcinoma of the skin",
                                "cervical carcinoma in situ",
                                "early stage prostate carcinoma not requiring active treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or lactation",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactation",
                    "criterion": "lactation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with checkpoint inhibitors, CTL-4 antibody or other immunotherapy agents",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with checkpoint inhibitors",
                    "criterion": "prior treatment with checkpoint inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... CTL-4 antibody",
                    "criterion": "prior treatment with CTL-4 antibody",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... other immunotherapy agents",
                    "criterion": "prior treatment with other immunotherapy agents",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant acute or chronic infections including, among others: HIV, AIDS, HBV",
            "criterions": [
                {
                    "exact_snippets": "Significant acute or chronic infections",
                    "criterion": "infections",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "AIDS",
                    "criterion": "AIDS",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HBV",
                    "criterion": "HBV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior organ transplantation, including allogeneic stem cell transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior organ transplantation",
                    "criterion": "organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allogeneic stem cell transplantation",
                    "criterion": "allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of autoimmune disorder except diabetes mellitus type 1, vitiligo or hypothyroidism only requiring hormone replacement",
            "criterions": [
                {
                    "exact_snippets": "Known history of autoimmune disorder except diabetes mellitus type 1, vitiligo or hypothyroidism only requiring hormone replacement",
                    "criterion": "autoimmune disorder",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "diabetes mellitus type 1",
                                "vitiligo",
                                "hypothyroidism only requiring hormone replacement"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior placement of intracavitary BCNU-impregnated wafers (Gliadel).",
            "criterions": [
                {
                    "exact_snippets": "Prior placement of intracavitary BCNU-impregnated wafers (Gliadel)",
                    "criterion": "intracavitary BCNU-impregnated wafer (Gliadel) placement",
                    "requirements": [
                        {
                            "requirement_type": "history of placement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received any other therapeutic investigational agent within 30 days of enrollment with the exception of the personalized MTA vaccine (NCT03223103) that can be continued throughout the study.",
            "criterions": [
                {
                    "exact_snippets": "received any other therapeutic investigational agent within 30 days of enrollment",
                    "criterion": "receipt of other therapeutic investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of the personalized MTA vaccine (NCT03223103) that can be continued throughout the study",
                    "criterion": "receipt of personalized MTA vaccine (NCT03223103)",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received any other therapeutic investigational agent within 30 days of enrollment or prior",
            "criterions": [
                {
                    "exact_snippets": "received any other therapeutic investigational agent within 30 days of enrollment or prior",
                    "criterion": "receipt of other therapeutic investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Patients must have adequate bone marrow, hepatic and renal function and hemoglobin and the test musts be performed within 14 days prior to study Day 1.",
            "criterions": [
                {
                    "exact_snippets": "adequate bone marrow",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate hepatic",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... hemoglobin",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the test musts be performed within 14 days prior to study Day 1",
                    "criterion": "laboratory test timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to study Day 1"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "Contact site for full inclusion/exclusion list.",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}